Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma A Systematic Review and Network Meta-analysis


LI, TJ; Lindsley, K; Rouse, B; Hong, H; Shi, QY; Friedman, DS; Wormald, R; Dickersin, K; (2016) Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma A Systematic Review and Network Meta-analysis. Ophthalmology, 123 (1). pp. 129-140. ISSN 0161-6420 DOI: 10.1016/j.ophtha.2015.09.005

Full text not available from this repository.

Abstract

Topic: Primary open-angle glaucoma (POAG) is a highly prevalent condition worldwide and the most common cause of irreversible sight loss. The objective is to assess the comparative effectiveness of first-line medical treatments in patients with POAG or ocular hypertension through a systematic review and network meta-analysis, and to provide relative rankings of these treatments. Clinical Relevance: Treatment for POAG currently relies completely on lowering the intraocular pressure (IOP). Although topical drops, lasers, and surgeries can be considered in the initial treatment of glaucoma, most patients elect to start treatment with eye drops. Methods: We included randomized controlled trials (RCTs) that compared a single active topical medication with no treatment/placebo or another single topical medication. We searched CENTRAL, MEDLINE, EMBASE, and the Food and Drug Administration's website. Two individuals independently assessed trial eligibility, abstracted data, and assessed the risk of bias. We performed Bayesian network meta-analyses. Results: We included 114 RCTs with data from 20 275 participants. The overall risk of bias of the included trials is mixed. The mean reductions (95% credible intervals) in IOP in millimeters of mercury at 3 months ordered from the most to least effective drugs were as follows: bimatoprost 5.61 (4.94; 6.29), latanoprost 4.85 (4.24; 5.46), travoprost 4.83 (4.12; 5.54), levobunolol 4.51 (3.85; 5.24), tafluprost 4.37 (2.94; 5.83), timolol 3.70 (3.16; 4.24), brimonidine 3.59 (2.89; 4.29), carteolol 3.44 (2.42; 4.46), levobetaxolol 2.56 (1.52; 3.62), apraclonidine 2.52 (0.94; 4.11), dorzolamide 2.49 (1.85; 3.13), brinzolamide 2.42 (1.62; 3.23), betaxolol 2.24 (1.59; 2.88), and unoprostone 1.91 (1.15; 2.67). Conclusions: All active first-line drugs are effective compared with placebo in reducing IOP at 3 months. Bimatoprost, latanoprost, and travoprost are among the most efficacious drugs, although the within-class differences were small and may not be clinically meaningful. All factors, including adverse effects, patient preferences, and cost, should be considered in selecting a drug for a given patient. (C) 2016 by the American Academy of Ophthalmology.

Item Type: Article
Keywords: MULTIPLE-TREATMENTS METAANALYSIS, MIXED TREATMENT COMPARISONS, RANDOMIZED-TRIALS, UNITED-STATES, INCONSISTENCY, CONSISTENCY, REGRESSION, INTERVENTIONS, MANAGEMENT, PAIRWISE
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Clinical Research
Research Centre: The International Centre for Evidence in Disability
International Centre for Eye Health
PubMed ID: 26526633
Web of Science ID: 367060700035
URI: http://researchonline.lshtm.ac.uk/id/eprint/2530979

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
168Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item